Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · June 27, 2023

Tolerability, Safety, and Pharmacodynamics of Danuglipron for Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes
Diabetes Obes Metab 2023 Jun 13;[EPub Ahead of Print], AR Saxena, JP Frias, DN Gorman, RN Lopez, N Andrawis, N Tsamandouras, MJ Birnbaum

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading